BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Shire Plc Poaches Bayer AG (BAY.F) Exec for Top Job


10/25/2012 8:27:09 AM

Bayer Corporation | Jobs at Bayer Corporation
Shire Pharmaceuticals | Jobs at Shire Pharmaceuticals

Shire Plc (SHP) said Bayer AG (BAYN)’s Flemming Ornskov will take over as chief executive officer of the world’s biggest maker of attention-deficit disorder drugs, following the retirement of Angus Russell next year. Russell, 56, has been with Shire for 13 years and has worked in the pharmaceutical industry for 32 years, the Dublin- based company, which has management offices in Basingstoke, England, said today in a statement. The company also reported third-quarter profit that missed analysts’ estimates. Ornskov joins Shire from Leverkusen, Germany-based Bayer, where he worked as chief marketing officer and global head of strategic marketing for general and specialty medicine. He takes over a company with a market value exceeding 10 billion pounds ($16 billion) and annual sales of $4.2 billion, built by Russell with more than two dozen acquisitions since 1999. “When I joined it, we were this little specialist company that was like others, reformulating” medicines, Russell said on a conference call with journalists. “That became a model that wasn’t sustainable. Then we got into rare genetic diseases. Now we’re forging our own way.”


Read at BusinessWeek
Read at Reuters
Read at Philadelphia Inquirer

Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES